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dated. Overall, 16 (39%) of studies detected a statisti-
cally significant HRQoL difference associated with any
prostate cancer treatment, 6 (37.5%) of which are single-
treatment studies with pre-post designs, 10 (62.5%) of
which are between-treatment studies. 
CONCLUSIONS: Selection of appropriate HRQoL-max-
imizing therapies for prostate cancer patients requires in-
formation on competing alternatives. Currently, the liter-
ature does not adequately address this need. Generic
measures have not been responsive to treatment-related
changes in HRQoL for prostate cancer. More work is
needed to develop sensitive and externally valid measures of
the multiple approaches to treating prostate cancer.
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OBJECTIVE: Little has been reported on the frequency
of complementary and alternative medicine (CAM) treat-
ments among prostate cancer (PCa) patients despite
growing use in other conditions. This research reports on
utilization of CAM treatments among a group of recently
diagnosed PCa patients. 
METHODS: We identified a cohort of 995 newly diag-
nosed PCa patients enrolled in CaPSURE, a longitudinal
observational database. Patients report on the use of
CAM treatments in quarterly, self-administered question-
naires. Patients indicate whether or not they have used
CAM and then indicate the specific treatment. Chiro-
practic visits are not considered an alternative therapy in
this database. 
RESULTS: Mean age of patients was 75.9 years. Patients
were 71% white and 11% African American, 44% had
some college, median income was $30,000. Median fol-
low-up was 12 months. CAM treatment was reported by
36.4% of patients. The most frequently reported CAM
treatments were: 1) herbal medicine (including Chinese
herbs, other herbs, saw palmetto, and St. John’s Wort),
19.2%; 2) diet, nutrition, and lifestyle modification (such
as smoking cessation or exercise), 9.7%; 3) vitamins/min-
erals, 8.3%; 4) acupuncture, 4.9%; 5) homeopathic reme-
dies, 3.1%; 6) meditation and biofeedback, 1.8%. Other
treatments included: massage/bodywork, immune enhanc-
ers, hypnotherapy, and miscellaneous items such as pet
adoption. 
CONCLUSIONS: We found that a significant proportion
of newly diagnosed PCa patients (36%) reported use of
CAM treatments. These results are similar to data re-
ported for other chronic conditions, such as arthritis,
HIV-infection, and other cancers where 30–60% of pa-
tients report use of CAM therapies. Further research into
the benefit of these therapies in terms of improved pa-
tient functioning is needed.
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Current literature suggests that nearly 18% of lifetime
costs for medical care ($40,000 per person) is estimated
to be incurred in the last year of life and nearly 28% of
US Medicare payments for those over age 65 are for per-
sons in their last year of life (Scitoversusky 1994). Little
has been reported, however, on total medical costs at the
end-of-life for prostate cancer (PCa) patients. 
OBJECTIVE: The aim of this research was to compare
the last year of medical costs in PCa patients dying at
home or in an healthcare institution. 
METHODS: Cost data was extracted on 293 men from
CaPSURE, a longitudinal disease registry of patients with
PCa. Standard charges (1997 dollars) were applied to all
healthcare services in the last four quarters of life. Not all
patients contributed data to each quarter. Descriptive
and multivariate analyses were used to examine cost dif-
ferences between groups. 
RESULTS: About 63% of patients died in institutions,
while 31% died at home. PCa was the reported cause of
death in 32.8% of cases. After controlling for time pe-
riod, location and cause of death, total medical costs
were lower in the last 3 months of life for PCa patients
who died at home ($1975 versus $3179, p  0.05). No
statistical differences were found in the preceding three
quarters. 
CONCLUSIONS: Total medical costs in the last 3
months of life were lower for PCa patients who die at
home when compared with those dying in healthcare in-
stitutions. Inpatient care costs were nearly three times
higher for patients dying in healthcare institutions. These
cost savings may inform the way we meet the challenge
to improve the quality of life, but also the quality of
death among PCa patients at the end-of-life.
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